Tg Therapeutics (TGTX) Return on Capital Employed (2012 - 2026)
Tg Therapeutics (TGTX) posted quarterly Return on Capital Employed of 13.48% for Q1 2026, up 39.0% year-over-year from 9.7% in Q1 2025, and down 2.67% quarter-over-quarter from 13.85% in Q4 2025.
Tg Therapeutics (TGTX) Return on Capital Employed (2012 - 2026) Analysis & Trends
Tg Therapeutics' Return on Capital Employed history runs 15 years deep, the most recent figure standing at 13.48% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 39.0% year-over-year to 13.48%; the TTM figure through Mar 2026 stood at 13.48% (up 39.0% YoY), while the FY2025 annual figure was 18.5%, up 695.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 13.48%, down from 13.85% in the prior quarter.
- The five-year high for Return on Capital Employed was 36.56% in Q2 2024, with the low at 143.13% in Q4 2022.
- The 5-year median for Return on Capital Employed is 7.46% (2023), against an average of 38.6%.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed plunged 4929 bps in 2022, then jumped 17887 bps in 2024.
- Tg Therapeutics' Return on Capital Employed stood at 143.13% in 2022, then jumped by 105 bps to 7.46% in 2023, then rose by 14 bps to 8.54% in 2024, then soared by 62 bps to 13.85% in 2025, then retreated by 3 bps to 13.48% in 2026.
- Business Quant data shows TGTX's Return on Capital Employed at 13.48% in Q1 2026, 13.85% in Q4 2025, and 14.54% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 10.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.36% |
| Mar 31, 2026 | 13.48% |
| Dec 31, 2025 | 13.85% |
| Sep 30, 2025 | 14.54% |
| Jun 30, 2025 | 16.91% |
| Mar 31, 2025 | 13.09% |
| Dec 31, 2024 | 8.54% |
| Sep 30, 2024 | -0.14% |
| Jun 30, 2024 | 36.56% |
| Mar 31, 2024 | 19.21% |
| Dec 31, 2023 | 7.46% |
| Sep 30, 2023 | -20.35% |
| Jun 30, 2023 | -142.31% |
| Mar 31, 2023 | -142.33% |
| Dec 31, 2022 | -143.13% |
| Sep 30, 2022 | -117.84% |
| Jun 30, 2022 | -121.31% |
| Mar 31, 2022 | -112.48% |
| Dec 31, 2021 | -104.71% |
| Sep 30, 2021 | -94.61% |